ABI
EXEL icon

Adamant Biomedical Investments’s Exelixis EXEL Stock Holding History

Adamant Biomedical Investments’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$432K Hold
300,000
– – 0.1% 94
2014
Q3 		$459K Buy
+300,000
New +$963K 0.11% 89

Other funds holding EXEL

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adamant Biomedical Investments's EXEL Position: Q4 2014 in Review

Adamant Biomedical Investments held its Exelixis (EXEL) position steady in Q4 2014 at 300,000 shares worth $432K. The position accounts for 0.1% of the portfolio, ranked #94.

Adamant Biomedical Investments first reported a position in EXEL in Q3 2014 and has held it in 2 quarters since. The position peaked at $459K in Q3 2014. 124 funds tracked by Wall St. Rank hold EXEL as of Q4 2014.

  • Adamant Biomedical Investments held 300,000 shares of Exelixis worth $432K as of Q4 2014.
  • Adamant Biomedical Investments left its Exelixis share count unchanged in Q4 2014.
  • Exelixis made up 0.1% of Adamant Biomedical Investments's portfolio in Q4 2014, its #94 holding.
  • Adamant Biomedical Investments first reported a position in Exelixis in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Exelixis position peaked at $459K in Q3 2014.
  • 124 funds tracked by Wall St. Rank held Exelixis as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.